Capital Research Global Investors Haemonetics Corp Transaction History

Capital Research Global Investors

$440 Billion
Q1 2025

A detailed history of Capital Research Global Investors transactions in Haemonetics Corp stock. As of the latest transaction made, Capital Research Global Investors holds 1,577,323 shares of HAE stock, worth $122 Million. This represents 0.02% of its overall portfolio holdings.

Number of Shares

1,577,323

Previous 4,238,954 62.79%

Holding current value

$122 Million

Previous $331 Million 69.71%

% of portfolio

0.02%

Previous 0.07%

27 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 12, 2025	SELL	$59.34 - $80.05 $158 Million - $213 Million	-2,661,631 Reduced 62.79%	1,577,323 $100 Million
Q4 2024 Feb 13, 2025	SELL	$71.16 - $93.38 $14.5 Million - $19 Million	-203,699 Reduced 4.59%	4,238,954 $331 Million
Q3 2024 Nov 13, 2024	SELL	$72.45 - $91.58 $179 Million - $226 Million	-2,472,556 Reduced 35.76%	4,442,653 $357 Million
Q2 2024 Aug 13, 2024	BUY	$81.24 - $97.37 $19.5 Million - $23.4 Million	240,458 Added 3.6%	6,915,209 $572 Million
Q1 2024 May 14, 2024	BUY	$71.24 - $85.35 $10.8 Million - $12.9 Million	151,183 Added 2.32%	6,674,751 $570 Million
Q4 2023 Feb 13, 2024	SELL	$80.59 - $92.61 $8.03 Million - $9.22 Million	-99,580 Reduced 1.5%	6,523,568 $558 Million
Q3 2023 Nov 13, 2023	SELL	$82.56 - $93.49 $5.48 Million - $6.21 Million	-66,391 Reduced 0.99%	6,623,148 $593 Million
Q2 2023 Aug 11, 2023	BUY	$80.84 - $89.45 $2.89 Million - $3.2 Million	35,797 Added 0.54%	6,689,539 $570 Million
Q1 2023 May 15, 2023	BUY	$72.75 - $90.6 $50.8 Million - $63.2 Million	697,678 Added 11.71%	6,653,742 $551 Million
Q4 2022 Feb 14, 2023	SELL	$73.85 - $86.14 $24.4 Million - $28.4 Million	-330,212 Reduced 5.25%	5,956,064 $468 Million
Q3 2022 Nov 14, 2022	BUY	$63.3 - $78.66 $306,372 - $380,714	4,840 Added 0.08%	6,286,276 $465 Million
Q2 2022 Aug 15, 2022	BUY	$49.27 - $66.08 $40.9 Million - $54.8 Million	829,430 Added 15.21%	6,281,436 $409 Million
Q1 2022 May 16, 2022	BUY	$43.77 - $63.22 $149 Million - $215 Million	3,402,873 Added 166.06%	5,452,006 $345 Million
Q4 2021 Feb 14, 2022	BUY	$49.55 - $74.59 $45.4 Million - $68.3 Million	915,385 Added 80.74%	2,049,133 $109 Million
Q3 2021 Nov 15, 2021	SELL	$57.6 - $70.59 $89 Million - $109 Million	-1,545,588 Reduced 57.69%	1,133,748 $80 Million
Q2 2021 Aug 16, 2021	SELL	$51.81 - $118.56 $183 Million - $419 Million	-3,538,162 Reduced 56.91%	2,679,336 $179 Million
Q1 2021 May 14, 2021	BUY	$111.01 - $139.48 $64.4 Million - $80.9 Million	579,763 Added 10.28%	6,217,498 $690 Million
Q4 2020 Feb 12, 2021	BUY	$88.75 - $119.95 $72.1 Million - $97.4 Million	812,220 Added 16.83%	5,637,735 $669 Million
Q3 2020 Nov 13, 2020	BUY	$75.65 - $93.58 $63.4 Million - $78.4 Million	837,512 Added 21.0%	4,825,515 $421 Million
Q2 2020 Aug 14, 2020	BUY	$84.96 - $118.91 $93 Million - $130 Million	1,094,203 Added 37.81%	3,988,003 $357 Million
Q1 2020 May 15, 2020	BUY	$74.34 - $121.82 $14.8 Million - $24.2 Million	199,000 Added 7.38%	2,893,800 $288 Million
Q4 2019 Feb 18, 2020	BUY	$114.37 - $129.46 $16.4 Million - $18.6 Million	143,800 Added 5.64%	2,694,800 $310 Million
Q2 2019 Aug 14, 2019	BUY	$81.74 - $120.34 $93.1 Million - $137 Million	1,138,850 Added 80.65%	2,551,000 $307 Million
Q4 2018 Feb 14, 2019	SELL	$90.66 - $116.63 $19.2 Million - $24.7 Million	-211,850 Reduced 13.04%	1,412,150 $141 Million
Q2 2018 Aug 14, 2018	BUY	$71.53 - $95.75 $28.6 Million - $38.3 Million	400,000 Added 32.68%	1,624,000 $146 Million
Q1 2018 May 15, 2018	BUY	$60.72 - $74.41 $52.9 Million - $64.8 Million	870,541 Added 246.29%	1,224,000 $89.5 Million
Q4 2017 Feb 14, 2018	BUY	$44.96 - $58.99 $15.9 Million - $20.9 Million	353,459	353,459 $20.5 Million

Others Institutions Holding HAE

# of Institutions

351

Shares Held

53.3M

Call Options Held

417K

Put Options Held

314K

View Full List

About HAEMONETICS CORP

Ticker HAE
Exchange NYSE
Sector Healthcare
Industry Medical Instruments & Supplies
Shares Outstandng 51,316,500
Market Cap $3.98B
Description
Haemonetics Corporation, a healthcare company, provides medical products and solutions. It operates through three segments: Plasma, Blood Center, and Hospital. The company offers automated plasma collection devices, related disposables, and software, including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and intravenous s...

More about HAE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Capital Research Global Investors, based on Form 13F filings with the SEC.

News

Stay updated on Capital Research Global Investors with notifications on news.

Account

Capital Research Global Investors Haemonetics Corp Transaction History